Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

View All Documentation

SML2282

Sigma-Aldrich

Everolimus

≥95% (HPLC), powder, P-glycoprotein substrate

Sinônimo(s):

Everolimus, 40-O-(2-Hydroxyethyl)rapamycin, 42-O-(2-Hydroxyethyl)-rapamycin, RAD 001, RAD001, SDZ-RAD, 42-O-(2-Hydroxyethyl)rapamycin

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C53H83NO14
Número CAS:
159351-69-6
Peso molecular:
958.22
Número MDL:
MFCD00929329
Código UNSPSC:
12352200
NACRES:
NA.77

product name

Everolimus, ≥95% (HPLC)

Ensaio

≥95% (HPLC)

forma

powder

cor

white to beige

solubilidade

DMSO: 2 mg/mL, clear

Condições de expedição

wet ice

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

chave InChI

HKVAMNSJSFKALM-GKUWKFKPSA-N

Informações sobre genes

human ... FKBP1A(2280)

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Everolimus has been used as an mechanistic target of rapamycin complex 1 (mTORC1) inhibitor to study its effect on MCF7 and MDA-MB-231 cell lines.

Ações bioquímicas/fisiológicas

Everolimus, a substrate for P-glycoprotein (P-gp) can be used to treat advanced neuroendocrine tumors (NETs).
Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR). Everolimus is selective for the mTORC1 protein complex. Everolimus exhibit potent immunosuppressive and anticancer activities.

Pictogramas

Health hazardEnvironment
GHS08,GHS09

Palavra indicadora

Warning

Frases de perigo

H351,H361fd,H373,H410

Classificações de perigo

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2

Órgãos-alvo

Kidney,Testes

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Rapamycin Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus

Sigma-Aldrich

R8781

Rapamycin

Exemestane ≥98% (HPLC)

Sigma-Aldrich

PZ0006

Exemestane

Rapamycin from Streptomyces hygroscopicus ≥95% (HPLC), powder

Sigma-Aldrich

R0395

Rapamycin from Streptomyces hygroscopicus

6α-Methylprednisolone 21-hemisuccinate sodium salt lyophilized powder

Sigma-Aldrich

M3781

6α-Methylprednisolone 21-hemisuccinate sodium salt

mTOR Inhibitor XI, Torin1 mTOR Inhibitor XI, Torin1, CAS 1222998-36-8, is a cell-permeable, highly potent, ATP-competitive inhibitor of mTOR and DNA-PK (IC50 = 4.32 and 6.34 nM, respectively).

Sigma-Aldrich

475991

mTOR Inhibitor XI, Torin1

O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Barkovskaya A, et al.
Scientific Reports, 9(1), 5670-5670 (2019)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lee L, et al.
Expert Opinion on Pharmacotherapy, 19(8), 909-928 (2018)
Chemical modification of rapamycin: the discovery of SDZ RAD.
R Sedrani et al.
Transplantation proceedings, 30(5), 2192-2194 (1998-09-02)
Gerke Ariaans et al.
BMC cancer, 17(1), 232-232 (2017-03-31)
Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We investigated the glucose-dependent
Heidi A Lane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(5), 1612-1622 (2009-02-19)
Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular endothelial growth factor receptor (VEGFR) inhibitor vatalanib (PTK/ZK). Antiproliferative activity against various tumor histotypes and downstream effects on the mTOR pathway
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica